Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Slides:



Advertisements
Similar presentations
HIV and STD in Maine Data from the Bureau of Health HIV/STD Program Contact: Mark Griswold (207)
Advertisements

Florida Department of Health HIV/AIDS Section Division of Disease Control and Health Protection Annual data trends as of 12/31/2013 Living (Prevalence)
The Changing Well-being of Older Status First Nations Adults An Application of the Registered Indian Human Development Index Symposium on Aboriginal Experiences.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Wisconsin HIV/AIDS Surveillance Annual Review: Slide Set New diagnoses, prevalent cases, and deaths through December 2014 April 2015 P Wisconsin.
Adjusted Rates Nancy D. Barker. Adjusted Rates Crude Rates Table 1.
Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,
Late HIV Diagnoses, Georgia,
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Main Points to be Covered
HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,
SMRs, PMRs and Survival Measures Principles of Epidemiology Lecture 3 Dona SchneiderDona Schneider, PhD, MPH, FACE.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.
Epidemiology of HIV among Asians & Pacific Islanders Reported in Florida, Through 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Annual.
Epidemiology of HIV Among Asians and Pacific Islanders Reported in Florida, Through 2014 Florida Department of Health HIV/AIDS Section Division of Disease.
HIV/AIDS Epidemiology Update February 2009 Dr Nigel Dickson Director, AIDS Epidemiology Group Department of Preventive and Social Medicine University of.
Highlights from the HIV Surveillance Report, 2008 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance.
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
Measuring disease and death frequency
1 A Study of Incidence Experience for Taiwan Life Insurance Jack C. Yue and Hong-Chih Huang 2010/09/10 National Chengchi University Sixth International.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
HIV/AIDS among Women in Texas Enhanced Perinatal Surveillance May 30, 2007 Nita Ngo, MPH.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Florida Department of Health HIV/AIDS and Hepatitis Section Division of Disease Control and Health Protection Annual data trends as of 12/31/2012 Living.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
HIV Surveillance Report, 2010 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance System.
HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.
Florida Department of Health HIV/AIDS & Hepatitis Program Annual data trends as of 12/31/2012 Living (Prevalence) data as of 05/16/2012 Epidemiology of.
The case for HIV testing A presentation for the clinical team in your practice.
Lecture 5: The Natural History of Disease: Ways to Express Prognosis
Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,
Annual Epidemiological Spotlight on HIV in London: 2014 data Field Epidemiology Services PHE Publications gateway number
Lisa S BURCH, Natasha OAKES-MONGER, Colette J SMITH, Fiona C LAMPE, Rob TSINTAS, Clinton CHALONER, Anderw N PHILLIPS, Margaret A JOHNSON Research Department.
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Viral tropism by geno2pheno as.
Mean HIV viral load among resident cases and undiagnosed in Oregon Jeff Capizzi, Epidemiologist Sean Schafer, HIV/STD/TB Medical Epidemiologist Lea Bush,
Socio-economic factors and late diagnosis of HIV in in the Royal Free cohort Socio-economic factors and late diagnosis of HIV in in.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
HIV and STI Department The case for HIV testing A presentation for the clinical team in your practice.
Epidemiology of HIV Among Men in Florida, Reported through 2014 Florida Department of Health HIV/AIDS Section Division of Disease Control and Health Protection.
HIV Infections in Utah: 2014 Epidemic Update. Cases – persons diagnosed with HIV and reported to public health Rates – cases per 100,000 populations Sex.
Epidemiology of HIV Among Men in Florida, Reported through 2011 Florida Department of Health HIV/AIDS & Hepatitis Program Annual data as of 12/31/2011.
Why Late Diagnosis of HIV? Dr Faiza Khan Consultant in Public Health Kent County Council.
Epidemiology of HIV Among Asians and Pacific Islanders Reported in Florida, Through 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System Predictors for high viraemia among the treatment naïve population.
HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
Risk of tuberculosis following HIV seroconversion in low- burden tuberculosis countries Sara Lodi, Antonella d’Arminio Monforte, Julia del Amo, Sophie.
Instructional Objectives:
Earlier treatment and lower mortality in infants Initiating ART at
ART and toxicities: CNS
14th European AIDS Conference
HIV surveillance in Northern Ireland 2015
How do health expenditures vary across the population?
Poster P200 18th Annual Conference of the British HIV Association (BHIVA), 18 – 20th April 2012, Birmingham, UK An analysis of the reasons for switching.
Table 1: New HIV diagnoses, by UK country,
San Francisco Department of Public Health
Conflicting of interest disclosure: None
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Presentation transcript:

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol

Background UK CHIC Life expectancy (LE) is an important population health indicator that varies by country –Previous analyses of LE in HIV-1 infected individuals by ART- CC included few patients from UK (Royal Free only) and were averaged over several countries Lancet 372(2008): For patients, knowing LE may affect lifestyle decisions: –Whether to have children, treatment for co-morbidities, save for a pension… LE is also important for public health planning –estimating health burden of lifetime treatment with cARTg LE can be used by policy makers –Eg offers of life insurance depending on LE Mortgage and housing, providing for dependents

Aims UK CHIC To estimate for the UK population of HIV-1 infected individuals: Mortality rates (per 1000 pyears) –Overall –Between the ages 20 and 44 years Potential years of life lost (PYLL) before age 65 (per 1000 pyears) Life expectancy –At exact ages 20 and 35 –Percentage of patient surviving from 20 to 44 years

Aims UK CHIC To estimate these health indicators overall and by: –Period of follow up , , , –Gender and ethnicity White males, non-white males, white females, non-white females –CD4 cell count at start of cART <100, , cellscells/mm 3 –Year of starting cART , , To estimate these health indicators in those who survive at least 6 months from start of cART

Patients included in analysis UK CHIC Patients –attended one of the UK clinics that contribute data to UKCHIC –were aged 20 years and older –started cART on at least 3 drugs between 1996 and 2008 IDU were excluded Followed up for all cause mortality –Linkage to death registry –Administratively censored on 31 st December 2008 CD4 analysis restricted to the subset of patients who had a measurement in 3 months before start of cART –14868/17661 (84%) patients with CD4

Methods UK CHIC Crude mortality rates were calculated by dividing total no. deaths by total no. years follow up PYLL were calculated as the sum of years patients lost because of premature death before the age of 65 Abridged life tables were constructed from age-specific mortality rates in 5-year bands –These tables describe the mortality experience that hypothetical cohorts of individuals would have had if they were subjected to the mortality rates in the observed calendar periods –The life expectancy at an exact age is the average no. of additional years that will be lived by a person after that age, according to the cross-sectional age- specific mortality rates recorded during the study period

Table 1: Characteristics of patients at cART start UK CHIC (N=5849) (N=3609) (N=4180) (N=4023) 1996 – 2008 (N=17661) Age, median (IQR) 36 (31- 42)36 (32-42)37 (32-43)38 (32-44)37 (32-43) Gender and ethnicity N (%) Male White3856 (66)1703 (47)1965 (47)2077 (52)9601 (54) Male non-White953 (16)845 (23)984 (24)919 (23)3701 (21) Female White229 (3.9)120 (3.3)132 (3.2)116 (2.9)597 (3.4) Female non-White811 (14)941 (26)1099 (26)911 (23)3762 (21) Risk factor for transmission, N (%) MSM3835 (66)1697 (47)2067 (49)2025 (50)9624 (54) Heterosexual1517 (26)1593 (44)1863 (45)1521 (38)6494 (37) Other or unknown497 (8.5)319 (8.8)250 (6.0)477 (11.9)1543 (8.7) CD4 count, median (IQR)140 (50-230)149 (61-225)174 (90-235)200( )166 (75-241) AIDS stage C diagnosis2179 (37)1007 (28)828 (20)576 (14)4590 (26) HIV-1 RNA (log copies/mL) Median (IQR)4.9 ( )5.0 ( )4.9 ( )4.7 ( )4.9 ( ) No previous ART exposure3145 (54)3281 (91)4014 (96)3853 (96)14293 (81)

LE overall and by calendar period UK CHIC

Table 2: Health indicators stratified by period of follow-up UK CHIC Measure Period of Follow-up 1996 — — — — — 2008 Number patientsN=5471N=8493N=12029 N=15152 N=17661 Mortality rates (per 1000 pyears) Overall 26.8 (23.7 – 30.1) 16.3 ( ) 12.2 (11.0 – 13.6) 9.5 ( ) 13.7 (12.9 – 14.5) Between the ages 20 and 44 years 22.7 ( ) 14.5 (12.7 – 16.7) 10.0 (8.6 – 11.5) 7.5 (6.4 – 8.8) 11.7 (10.9 – 12.6) Mortality rates are deaths per 1000 person-years (95% CI). SeStandard error for the estimated life expectancy

Table 2: Health indicators stratified by period of follow-up UK CHIC Measure Period of Follow-up 1996 — — — — — 2008 Number patientsN=5471N=8493N=12029 N=15152 N=17661 Mortality rates (per 1000 pyears) Overall 26.8 (23.7 – 30.1) 16.3 ( ) 12.2 (11.0 – 13.6) 9.5 ( ) 13.7 (12.9 – 14.5) Between the ages 20 and 44 years 22.7 ( ) 14.5 (12.7 – 16.7) 10.0 (8.6 – 11.5) 7.5 (6.4 – 8.8) 11.7 (10.9 – 12.6) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Mortality rates are deaths per 1000 person-years (95% CI). SeStandard error for the estimated life expectancy

Table 2: Health indicators stratified by period of follow-up UK CHIC Measure Period of Follow-up 1996 — — — — — 2008 Number patientsN=5471N=8493N=12029 N=15152 N=17661 Mortality rates (per 1000 pyears) Overall 26.8 (23.7 – 30.1) 16.3 ( ) 12.2 (11.0 – 13.6) 9.5 ( ) 13.7 (12.9 – 14.5) Between the ages 20 and 44 years 22.7 ( ) 14.5 (12.7 – 16.7) 10.0 (8.6 – 11.5) 7.5 (6.4 – 8.8) 11.7 (10.9 – 12.6) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)30.0 (1.2)39.4 (1.2)43.1 (1.0)45.8 (1.7)41.1 (0.5) At exact age 35 years (Se)20.0 (0.6)28.2 (0.6)31.6 (0.5)35.6 (0.5)30.8 (0.2) Mortality rates are deaths per 1000 person-years (95% CI). SeStandard error for the estimated life expectancy

Table 2: Health indicators stratified by period of follow-up UK CHIC Measure Period of Follow-up 1996 — — — — — 2008 Number patientsN=5471N=8493N=12029 N=15152 N=17661 Mortality rates (per 1000 pyears) Overall 26.8 (23.7 – 30.1) 16.3 ( ) 12.2 (11.0 – 13.6) 9.5 ( ) 13.7 (12.9 – 14.5) Between the ages 20 and 44 years 22.7 ( ) 14.5 (12.7 – 16.7) 10.0 (8.6 – 11.5) 7.5 (6.4 – 8.8) 11.7 (10.9 – 12.6) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)30.0 (1.2)39.4 (1.2)43.1 (1.0)45.8 (1.7)41.1 (0.5) At exact age 35 years (Se)20.0 (0.6)28.2 (0.6)31.6 (0.5)35.6 (0.5)30.8 (0.2) Percent surviving from 20 to 44 years60.8%74.7%81.6%82.3%77.3% Mortality rates are deaths per 1000 person-years (95% CI). SeStandard error for the estimated life expectancy

Table 3: Health indicators stratified by gender and ethnicity UK CHIC Measure Category White Males Non-White Males Number patientsN=9601N=3701 Mortality rates (per 1000 pyears) Overall 14.9 ( ) 14.9 (13.2 – 16.9) Between the ages 20 and 44 years 12.2 ( ) 14.1 (12.1 – 16.4) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)39.2 (1.2)40.3 (1.7) At exact age 35 years (Se)30.0 (0.3)30.6 (0.7) Percent surviving from 20 to 44 years74.7%74.1%

Table 3: Health indicators stratified by gender and ethnicity UK CHIC Measure Category White Males Non-White Males White Females Non-White Females Number patientsN=9601N=3701N=597N=3762 Mortality rates (per 1000 pyears) Overall 14.9 ( ) 14.9 (13.2 – 16.9) 11.0 (7.8 – 15.3) 10.4 (9.0 – 12.0) Between the ages 20 and 44 years 12.2 ( ) 14.1 (12.1 – 16.4) 10.6 (7.1 – 15.7) 9.6 (8.1 – 11.4) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)39.2 (1.2)40.3 (1.7)50.8 (3.4)47.0 (1.3) At exact age 35 years (Se)30.0 (0.3)30.6 (0.7)39.8 (2.5)35.1 (1.1) Percent surviving from 20 to 44 years74.7%74.1%80.0%82.4%

Table 4: Health indicators stratified by CD4 count UK CHIC Measure CD4 cell count < 100 cells/mm cells/mm cells/mm 3 Number patientsN=4585N=4434N=5849 Mortality rates (per 1000 pyears) Overall21.0 ( ) 12.1 ( ) 8.0 ( ) Between the ages 20 and 44 years19.1 ( ) 9.3 ( ) 6.6 ( ) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)34.9 (1.3) 41.0 (1.6) 51.7 (1.2) At exact age 35 years (Se)26.1 (0.44) 40.6 (0.5) 39.8 (0.7) Percent surviving from 20 to 44 years66.8% 79.9% 86.4% CD4 cell count at start of cART (N=14868).

Table 5: Health indicators stratified by year of starting cART UK CHIC Have not estimated for as fup too short Measure Year of starting cART Number patientsN=5849N=3609N=4180 Mortality rates (per 1000 pyears) Overall15.9 ( ) 10.9 ( ) 10.0 ( ) Between the ages 20 and 44 years14.2 ( ) 9.0 ( ) 7.8 ( ) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)39.5 (0.99) 45.2 (0.7) 45.4 (0.8) At exact age 35 years (Se)30.0 (0.32) 32.5 (0.7) 32.4 (0.8) Percent surviving from 20 to 44 years73.5% 84.8% 86.7%

Summary of results UK CHIC The average LE at age 20 over the study period was 41 years –43 years in those who survived first 6 months after starting cART LE improved from 30 to 46 years between and –31 to 47 years in those who survived at least 6 months from start of cART –LE higher in ART-CC analysis which was restricted to naïve patients As in the background population, females have better LE than males by 7 years or more There is no difference in LE between white and non-white males –Very few white females 67%, 80% and 86% of patients aged 20 who start cART with CD4<100, , respectively survive to age 44

Limitations UK CHIC Only 13 years of cART follow up from 1996 –LE is extrapolating outside the range of the data using cross-sectional data Only 2% of patients were aged 60 years and over –Very imprecise mortality estimates in the age group that should have the highest mortality –Adjusted mortality rates in the highest age group using trends across younger ages and information on rates in the UK population Less than 4% of patients were white women so estimates for this group are imprecise Changes in LE over time might reflect changes in demographics (eg increase in proportion of women) as well as improvements in drugs/care

Conclusion UK CHIC Individuals treated for HIV infection in the UK can expect to live many years after starting cART, depending on their age/sex/CD4 count The average LE of HIV infected individuals remains less than in the background UK population (to be quantified), but there has been substantial improvement since 1996 Differences in LE between men and women partially reflect those in the background population, but may also be due to earlier diagnosis and treatment or better adherence and response to treatment in women The impact of HIV infection on PYLL could be reduced by initiating treatment at higher CD4 counts

Acknowledgements UK CHIC is funded by the Medical Research Council, UK (Grant number G ) Loveleen Bansi for data management Caroline Sabin, Mark Gompels for suggestions on analyses

Table 6: Health indicators stratified by period of follow up for patients who survived first 6 months of cART UK CHIC Only 196 deaths in 1 st 6 months, but 756 lost to fup or with fup shorter than 6 months. Measure Period of Follow-up 1996 — — — — — 2008 Number patientsN=4820N=7801N=11205 N=14225 N=16276 Mortality rates (per 1000 pyears) Overall 26.1 (22.7 – 30.0) 15.3 ( ) 11.2 (10.0 – 12.6) 9.0 ( ) 12.6 (11.9 – 13.4) Between the ages 20 and 44 years 22.1 ( ) 14.0 (12.1 – 16.2) 9.1 (7.8 – 10.6) 6.9 (5.8 – 8.1) 10.8 (10.0 – 11.7) Potential years of life lost before age 65 years (per 1000 pyears) 20 to 64 years Life expectancy (years;adjusted) At exact age 20 years (Se)31.2 (1.2)42.2 (1.2)44.6 (1.0)47.0 (1.9)42.9 (0.5) At exact age 35 years (Se)20.5 (0.7)30.8 (0.8)32.6 (0.5)36.4 (0.5)32.0 (0.2) Percent surviving from 20 to 44 years63.8%76.6%83.7%84.0%79.8%